Alamar Biosciences Highlights NULISA Data In 46 Presentations At CTAD 2026, Including 10 Oral Presentations
| Date | Time | Presentation Number and Title | Presenter |
| Mon, Nov 16 | 4:20 p.m. | OC3: Ultrasensitive Immunoassay for Plasma eMTBR-243 Quantification | Nicholas Ashton, Banner Sun Health Research Institute |
| Tue, Nov 17 | 8:30 to 9:10 a.m. (Symposium 2) | Symposium 2, Presentation 2: CSF and Plasma Biomarker Changes After Anti-Tau Therapy: Fluid Biomarker Results from the Autonomy Phase 2 Clinical Trial | Gallen Triana-Baltzer, Johnson & Johnson |
| Tue, Nov 17 | 8:30 to 9:10 a.m. (Symposium 2) | Symposium 2, Presentation 3: Biomarker Associations with Cognition: Results from the Autonomy Phase 2 Clinical Trial | Gil D. Rabinovici, UCSF |
| Tue, Nov 17 | 4:00 p.m. | OC18: Metabolic-Inflammatory Burden Identifies Attenuated Responders to Lifestyle Intervention and Supports GLP-1RA Combination-Trial Design: Evidence from the FINGER study | Adrian Noriega De La Colina, Broad Institute of MIT and Harvard / MIT |
| Wed, Nov 18 | 8:30 a.m. | OC19: Brain-Derived pTau217 Outperforms 328 Plasma Proteins for Association with Amyloid and Tau Accumulation and Cognitive Progression in the A4 and LEARN Studies | Robert Rissman, University of Southern California |
| Wed, Nov 18 | 2:40 p.m. | OC33: Harmonizing plasma pTau217 across immunoassay platforms: the Unified pTau217 Score (Units) | Wagner S. Brum, ZRO Imaging, Santiago de Compostela |
| Wed, Nov 18 | 4:45 p.m. | OC39: Combining Plasma p-Tau217 with Proteomic Signatures Enables Graded Risk Stratification for Alzheimer's Disease Progression | Menghan Liu, Washington University School of Medicine |
| Thu, Nov 19 | 9:25 a.m. | OC41: CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression | Thomas K. Karikari, University of Pittsburgh |
| Thu, Nov 19 | 1:05 p.m. | OC48: Dynamic changes in plasma biomarkers in patients treated with lecanemab: a longitudinal cohort study | Rui Mu, Washington University School of Medicine |
| Thu, Nov 19 | 1:50 p.m. | OC51: Plasma eMTBR-tau as a biomarker for chronic traumatic encephalopathy tau tangle neuropathology | Annalise E. Miner, Boston University CTE Center and ADRC |
See here for a full list of posters and presentations featuring NULISA data at CTAD 2026.
About Alamar Biosciences
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISATM technology and the ARGO® HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as“Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com.
Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding, the ability of the NULISA platform to generate proteomic insights and potential to help researchers gain an understanding of how patients will progress or respond to therapies. Any forward-looking statements in this press release are based on Alamar Biosciences' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences' forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to the execution of the collaboration with GSK, intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences' instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences' ability to protect its intellectual property, and the other risks described in Alamar Biosciences' filings with the U.S. Securities and Exchange Commission. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
CONTACT: Media Contact Alamar Biosciences, Inc.... Investor Relations Alamar Biosciences, Inc....
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment